Latest resource
Main deliverables
D5.4 Report on Interim Patient Engagement Open Forum
Main deliverable
D6.5 Patient Engagement Sustainability Roadmap
THE PARADIGM GAP ANALYSIS
D1.2 Criteria to assess how patient engagement expectations are met
D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations
Communications and External Engagement Plan
PARADIGM’s digital assets
Report on the first open Patient Engagement Forum
Evolution of the Patient Engagement Ecosystem
Medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.
PARADIGM – 1st Open Patient Engagement Forum 2018
Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM) had its first Open Patient Engagement Forum on the 10th of April in Brussels co-organised by PARADIGM, PFMD and EUPATI. The forum had four workshops focusing on prioritisation of the PARADIGM survey topics, building the PARADIGM story, assessing the value of patient engagement and utilising the survey to identify key stakeholders and most suited methodologies for the project. Follow the link for a short report on the events of the day: https://bit.ly/2yjGr01
Communications and External Engagement Plan
The Communications and Engagement plan lays down the map for PARADIGM communications activities throughout the project. It sets the guidelines for upcoming communication events, on stakeholders to reach, on the key messaging and the tools to use to reach them.
PARADIGM’s digital assets
The success of PARADIGM is closely linked to the dissemination and adoption of the outcomes of the project. PARADIGM aims at ensuring an extensive outreach to a broad set of stakeholders within the medicines development community at large. In order to do that a set of digital assets were developed.
Report on the first open Patient Engagement Forum
The PARADIGM consortium led by European Patients’ Forum and EFPIA held its first forum on 10th of April 2018, which was co-organized by EUPATI (European Patients’ Academy on Therapeutic Innovation) and PFMD (Patient Focused Medicines Development).
